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To the Editor: Surveys of neonatal diabetes in the UK and
Germany from more than a decade ago reported an incidence
of 1 in 400,000–450,000 live births [1, 2]. The permanent
form of neonatal diabetes mellitus (PNDM) accounted for
about half the cases, equating to a PNDM incidence of 1 in
800,000–900,000 live births. The definition of neonatal
diabetes used in these publications was a diagnosis of
diabetes within 4 weeks [1] or 6 weeks [2] of birth. HLA
genotype analysis has shown that permanent diabetes
diagnosed within the first 6 months of life is PNDM rather
than type 1 diabetes [3]. Using a definition of diagnosis
before 6 months, the incidence of PNDM was recently
calculated at 1 in 214,000 live births from the Slovakian
diabetes register [4]. We examined the incidence rates of
PNDM in three further European countries.
The incidence of neonatal diabetes for a country can be
calculated from the referral rate of cases to a diagnostic
laboratory and the annual birth rate, if all cases are referred
to that laboratory. This will be less than the true incidence if
not all cases are referred, but will still reflect a minimum
incidence. In 2001 the Exeter Peninsula Molecular Genetics
Laboratory based at the Royal Devon and Exeter Hospital
(Exeter, UK) began recruiting patients worldwide prior to
the discovery reported in 2004 that KCNJ11 mutations are
the most common cause of PNDM [5]. The highest referral
rates are in the UK, the Netherlands and Poland, where
there have been considerable educational initiatives to
inform clinicians of the free-of-charge diagnostic service
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for patients diagnosed with diabetes before 6 months of
age. Between 2001 and 2009, samples from 119 patients
(50.4% male) born between 1950 and 2005, diagnosed with
PNDM and with no documented remission from diabetes
were referred from the UK, the Netherlands and Poland.
Isolated diabetes occurred in 60 patients, three had pan-
creatic agenesis, six had features consistent with Wolcott–
Rallison syndrome and 40 had neurological symptoms. A
genetic diagnosis was obtained in 59 cases, with mutations
in KCNJ11 (n=32) and INS (n=10) being the most
common. All the procedures in the participating centres
were conducted in accordance with the Declaration of
Helsinki as revised in 2000, and patients or their guardians
gave written informed consent.
We calculated the minimum annual PNDM incidence
rate from 1950 to 2005 for the UK, the Netherlands and
Poland. This was calculated using the number of patients
referred who were born in a given year and dividing by
the number of live births in that year using data from the
United Nations Population Division (http://esa.un.org/
unpp/, accessed 1 March 2009). To avoid large influences
of stochastic variation that could occur with the low
numbers, the results from the three countries were
combined and the data were analysed in 5 year groups
from 1950 to 2005. Minimum observed PNDM incidence
ranged from <0.5 cases per million live births between
1950 and 1970, to about one case per million between 1970
and 1985, and increased between 1985 and 2005 from 1.9
to 3.8 cases per million (Fig. 1).
The most recent data (24 cases born between 2000 and
2005) showed an incidence of 3.8 cases per million live births
(one in 260,000) and this is comparable to the 4.6 cases per
million live births calculated from the eight cases reported to
the Slovakian registry between 1981 and 2004 [4]. An
incidence of at least one in 260,000 live births in these four
European countries is still much lower than in Oman, which
has the highest reported incidence of PNDM, with one in
45,000 live births between 1991 and 1995 [6]. In Oman,
consanguineous marriages are frequent (55%) and conse-
quently we would expect a high prevalence of recessive
forms of PNDM, which are rare in outbred populations.
The reported incidence of neonatal diabetes in Germany
(12 cases between 1977 and 1991) and the UK (two cases
in 1994 and 1995) was considerably lower at 1 in 400,000–
450,000 live births [1, 2], which corresponds to a PNDM
incidence of about 1 in 800,000–900,000 live births, as
approximately 50% of the neonatal diabetes cases remit.
One partial explanation is that the definition of neonatal
diabetes for these series was diagnosis in the first 4 or
6 weeks rather than the first 6 months of life. In our dataset,
62% of patients had been diagnosed before 7 weeks. The
finding that patients diagnosed with diabetes in the first
6 months have mutations in the PNDM-associated genes [7]
and a similar prevalence of type 1-predisposing HLA
genotypes as non-diabetic controls [3] strongly supports
the view that a cut-off of 6 months is appropriate.
Themajor limitation of our study is that the data were taken
from a single referral centre, to which all referrals were
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Fig. 1 Minimum observed
annual incidence of PNDM per
million live births per year for
5 year intervals from 1 January
1950 to 31 December 2004 in
Poland, the Netherlands and the
UK combined
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voluntary. We consider it likely that we identified all patients
from these three countries who had genetic testing for PNDM
during this time period. However, we could not ascertain
patients with PNDM who died or for other reasons were not
referred for genetic testing. The calculated incidence data
therefore represent the minimum incidence rather than the
actual incidence and will be an underestimate.
The incidence of PNDM, based on referral rates for
genetic testing, appears to have progressively increased
over time (Fig. 1) and was particularly low before 1985.
This has many possible explanations. It could reflect
increased survival with improved clinical care over time.
However, the uncertainty about the referral rates for genetic
testing means that the apparent increase in incidence over
time may in fact merely reflect a difference in the
proportion of cases referred. In support of this being a
factor, we noted that 66% of the patients were born after
1985 and were therefore likely to have been referred from a
paediatric rather than an adult clinic. Paediatricians are
more aware of recent advances in the genetic aetiology of
PNDM and the impact this has on treatment, with improved
control in approximately 90% of patients with ATP-
sensitive K+ channel (KATP channel) mutations when
insulin is replaced by sulfonylureas [8, 9]. In addition the
smaller numbers of patients in paediatric clinics make it
easier to identify those patients diagnosed before 6 months
and refer them for genetic testing. Adult patients with
PNDM are probably under-diagnosed and more effort
should be made to identify these patients, especially as
some may benefit from transfer from insulin to sulfonylurea
treatment.
In conclusion, based on genetic testing the recent
incidence of PNDM in the UK, the Netherlands and Poland
is at least 1 in 260,000 live births, in keeping with a recent
smaller study from Slovakia. This is considerably higher
than in previous incidence studies performed in the UK and
Germany 10 years ago. This is only partly explained by the
widening of the diagnostic age group and therefore suggests
in addition either increased survival or greater awareness of
the diagnosis resulting from the therapeutic advances seen
since the discovery of KATP channel mutations.
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